Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TCRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTScan Therapeutics doubles authorized shares to 600M following shareholder approval
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Shareholders approved doubling authorized common stock from 300 million to 600 million shares, effective May 20, 2026. This gives management significant capacity for future capital raises, acquisitions, or employee compensation.
Item 5.03 verify on EDGAR → -
medium
Certificate of Amendment to the company's Amended and Restated Certificate of Incorporation was filed with Delaware to implement the authorized share increase.
Item 5.03 verify on EDGAR → -
low
Katina Dorton and R. Keith Woods were elected as Class II directors for three-year terms ending in 2029, with strong shareholder support.
Item 5.07 verify on EDGAR → -
low
Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal 2026 with 38.5 million votes in favor.
Item 5.07 verify on EDGAR →
Summary
TScan Therapeutics held its 2026 Annual Meeting on May 20, where shareholders approved a significant increase in authorized common stock from 300 million to 600 million shares. The amendment became effective immediately upon filing with Delaware. This doubling of share authorization provides management with substantial flexibility for future financing activities, though it also creates potential for dilution if shares are issued.
Retail investors should understand that while no shares were actually issued, the company now has the capacity to raise capital or make acquisitions without returning to shareholders for approval. The strong shareholder support (approximately 81% for Dorton, 96% for Woods) suggests confidence in management's direction. Watch for any subsequent Form 4 filings or S-3 shelf registrations that would signal actual share issuance plans in the coming months.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
TScan held its 2026 Annual Meeting of Stockholders on May 20, 2026; filing appears incomplete with no material disclosures provided.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 20, 2026, TScan Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).
The company disclosed that it held its annual stockholder meeting on May 20, 2026. The filing references Item 5.03 which typically covers amendments to articles of incorporation or bylaws, but the text is incomplete and does not provide details of any actual amendments or changes.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Item 5.07 — Submission of Matters to a Vote of Security Holders filed; see Key Changes for terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
The stockholders of the Company elected Katina Dorton, J.D., M.B.A. and R. Keith Woods as Class II directors, each to serve for a three-year term ending at the annual meeting of stockholders to be held in 2029
Two Class II directors were elected to three-year terms through 2029. Katina Dorton received 19,665,447 votes for with 4,508,811 withheld, while R. Keith Woods received 23,305,311 votes for with 868,947 withheld. This represents routine board governance with no unexpected outcomes.
Added in current filing · verify on EDGAR →
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026
Shareholders ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026 with 38,497,976 votes for, 637,978 against, and 285,483 abstentions. This is a routine annual approval with strong shareholder support.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of TScan Therapeutics, Inc.
The company filed an amendment to its certificate of incorporation.Common reasons for such amendments include changes to authorized shares, corporate name changes, or modifications to shareholder rights.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify